Download Company Statement

U.S. FDA Completes Inspection at Biocon Biologics’ Facility at Biocon Campus, Bengaluru, India

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Bengaluru, Karnataka, India, September 04, 2025

The U.S. Food and Drug Administration (FDA) has completed a routine cGMP inspection at Biocon Biologics’ Drug Substance facility at Biocon Campus in Bengaluru, India.

The inspection was held between August 26, 2025, and September 3, 2025, covering drug substance manufacturing units, analytical QC laboratories, microbiology laboratories, and warehouses.

At the conclusion of the inspection, the U.S. FDA issued a Form 483 with five observations. These observations are procedural in nature and do not pertain to data integrity, systemic non-compliance, or quality oversight.

Biocon Biologics will submit a comprehensive Corrective and Preventive Action (CAPA) plan within the stipulated timeline and is confident in its ability to address all observations expeditiously.

The company does not anticipate any impact on supply of its commercial products.

Biocon Biologics remains committed to upholding the highest standards of Quality and Compliance, and working collaboratively with global regulatory agencies to ensure the safety, efficacy, and reliability of its products.

– Company Spokesperson

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree